Gold Prices Drop as Strong Dollar, Rising U.S.-Iran Tensions Weigh on Market Sentiment 
OpenAI Files Confidential IPO Draft as AI Giants Race Toward Public Markets 
Australian Consumer Sentiment Drops in June as Financial Concerns Weigh on Households 
Japan Wholesale Inflation Accelerates to 6.3% in May, Exceeding Forecasts 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
China Trade Surplus Surges in May 2026 as Exports and AI-Driven Imports Accelerate 
Trump Administration Defends Anthropic AI Restrictions in Ongoing Federal Lawsuit 
GM and Peak Energy Partner to Advance Sodium-Ion Battery Technology for Grid Storage 
Gold Prices Slide Nearly 2% Ahead of Key U.S. Inflation Data and Rising Middle East Tensions 
US Dollar Slips Ahead of Key Inflation Data as Middle East Tensions Weigh on Markets 
Oracle Stock Falls Despite Earnings Beat as Company Plans $40 Billion Financing for FY2027 
Kremlin Says New EU Sanctions Won’t Hurt Russian Banks 
New Zealand Unemployment and Inflation Debate Intensifies Ahead of 2026 Election 
Wall Street Ends Mixed as Iran Tensions, OpenAI IPO Filing, and Inflation Concerns Weigh on Markets 
Sigma Healthcare Shares Slide Amid Preliminary Boots Acquisition Talks 
Trump Signals Opposition to USMCA Renewal as U.S. Reviews Trade Relations with Canada and Mexico 
Asian Stocks Rebound as AI and Chip Shares Recover; Easing Iran Tensions Boost Sentiment 
Samsung Biologics Co. was revealed to have won a new CMO contract deal with Pfizer Ireland Pharmaceuticals. The order is said to be worth $183 million, which is equivalent to 15.4% of Samsung Biologic's total sales profits in 2021.
Samsung Biologics is currently the no. 1 contract drug maker in the world based on production capacity. It has bagged this huge contract manufacturing organization (CMO) order from the Ireland unit of Pfizer Inc. the deal just raised expectations that the biotech division of Samsung Group's orders for this year will reach a new record high.
As per The Korea Economic Daily, Samsung Biologics announced its new CMO order through a regulatory filing on Thursday, March 2. Although this was only revealed now, the actual order was made by Pfizer Ireland Pharmaceuticals Ringaskiddy on Feb. 28.
Then again, the biotech firm did not mention the name of the medicine that it will make for Pfizer. It was stated in the contract that the manufacturing will run from Feb. 20, 2023, to Dec. 31, 2029.
In any case, this is the first time that Samsung Biologics or any Korean company has signed a CMO deal with the New York-headquartered pharmaceutical and biotech firm. Korea Joongang Daily reported with the latest business announcement, Samsung Biologics now boasts of having seven of the world's top 10 largest pharmaceutical firms as clients.
The Korean biotech company was established in 2011, and it has started partial operation of its fourth factory in Songdo, Incheon, just recently. This facility will have the capacity to produce 240,000 liters when it goes into full operation in June. This is said to be the largest single pharma production facility in the world.
Meanwhile, Samsung Biologics is investing another KRW 7.5 trillion or about $5.7 billion to build four new plants inside a manufacturing complex near its existing plants in the Songdo region.
